Beur schreef op 8 mei 2015 22:05:
[...]Dit is al jaren bekend en kon je bijvoorbeeld terugvinden in het assessment report van Ruc door de EMA:
"The pharmacokinetic data derived from the phase 1 trials demonstrated that the half-life of rhC1INH is shorter than pdC1INH which is due to the different glycosylation of rhC1INH (leading to more rapid hepatic
.....
treatments, Berinert®. All other known versions of recombinant C1 Inh, including e.g. Ruconest® from transgenic rabbits, displayed so far a significantly shorter half life than plasma derived C1 Inh. To achieve this excellent protein quality of the recombinant C1Inh, new glycosylation optimized CAP-GO cells were developed at CEVEC"